NEW YORK, NY / ACCESSWIRE / June 22, 2020 / Making a positive impact is a passion and a mission grounded on a set of beliefs and principles that have been shaped by the wheel of life. As hurdles in life become overwhelming, people tend to lose everything and overlook the purpose behind all these struggles.

However, for R&B singer, songwriter, and entrepreneur Waseem X, he took the wheel of life as a tool for recovery and an opportunity for him to make a positive impact on society, most especially to the youth. Born in Phoenix, Arizona, Waseem has dealt with a lot of trauma while growing up. It started with the divorce of his parents and then the abuses he received from his mother and stepfather. In 2017, the worst events happened when he lost his first child to a miscarriage, his sister got killed in a tragic car accident, and his father was unjustly incarcerated.

As negativity surrounded him, Waseem turned to smoking weed and drinking alcohol heavily to cope with all the stress and trauma in his life. For four years straight, he led a life full of negativity, and yet, like a leap of faith, he turned to the wheel of life and decided to change himself.

With the sudden drive to change his life, Waseem wanted to create a positive impact on his community. As a reflection of his life's experiences, he opened two businesses in health and fashion with a mission to give back to the community and promote self-improvement.

Waseem received a certification in Health and Nutrition Life Coaching and started his first business, "A Life Without Disease," in partnership with Wellevate By Emerson Ecologics. It is an online platform that promotes the best health and nutrition through life coaching, medical appointments, and supplements. Believing that good health is a right that everyone deserves, Waseem explains that "A Life Without Disease" represents the value of freedom.

Following the success of his first business, Waseem founded "Monarchs," a luxury athleisure clothing, footwear, and accessories company. It is an online luxury fashion store serving customers all over the world. His passion for helping others towards self-improvement led him to design his own luxury fashion brand that represents equality and royalty.

About a year later, Waseem launched a record label called "Star Icon," a platform that connects artists to a global music network of opportunities. It also allows artists, producers, and songwriters to sell their content in a decentralized platform using blockchain technology. As he believes that artists deserve 100% transparency with their record labels, with Star Icon, justice is the core value that it represents.

Waseem X is an inspiration to the youth. He is creating a positive impact through his businesses that are grounded in the mission of giving back and promoting self-improvement. He always wanted to do something better and take affirmative actions to make it happen. The hurdles in Waseem's life molded him into maximizing his full potential by not giving up. His advocacy on helping others continues to be an inspiration; he is looking forward to the youth to do the same.

To know more about Waseem X and his advocacy, visit his official website and follow him on Instagram. You can also reach out by calling (623) 226-0405 and sending an email to mgmt@therealwaseemx.com.

SOURCE: Authority Titans

ReleaseID: 594863

Developers working on methicillin-resistant staphylococcus aureus (MRSA) treatments market are expected to invest resources into research and development activities, for the generation of new product options, in a bid to bring in additional funding to the industry.

DUBAI, UAE / ACCESSWIRE / June 22, 2020 / Rising investments in the biopharmaceutical industry in response the coronavirus pandemic, has generated new opportunities for the methicillin-resistant staphylococcus aureus treatment market. Extensive resources being invested into R&D in public and private sectors will aid the MRSA treatment market to sustain growth through the pandemic.

The global methicillin-resistant staphylococcus aureus (MRSA) treatment market has managed to reach a valuation of 3.57 Bn in 2019. Similar to the coronavirus, MRSA is highly contagious and has a higher morbidity and mortality rate. Consequently, the investments in coronavirus treatment infrastructure will also aid MRSA treatments. On the other hand, the prioritization of resources to the COVID-19 crisis potentially creates shortages in MRSA treatments till the outbreak is brought under control.

"Researchers are focused on the development and introduction of new antibacterial drugs for MRSA-related diseases. Pharmaceutical companies, have gained approval for trial applications for existing drug formulations to combat MRSA- based post-surgery infections. These trends will sustain market growth through and after the duration of the pandemic," says the FMI analyst.

Request a report sample to gain in-depth market insights at https://www.futuremarketinsights.com/reports/sample/rep-gb-10406

Methicillin-Resistant Staphylococcus Aureus (MRSA) Treatments Market – Top Takeaways

Lipopeptide drug class contributes substantially to revenue share owing to effective distribution infrastructure
Streptogramins and fluoroquinolones will witness a superior growth rate owing to the rising MRSA incidences in developing economies
Parenteral administration accounts for major revenue share as a first line therapy in the market
While hospital pharmacies are the primary distribution channels for MRSA drugs, online channels are gaining ground, driven by discounts and product offers
North America will remain the dominant regional market owing to the presence of major market players. However, higher awareness about antibiotic resistant bacteria will drive growth in Asia Pacific

Methicillin-Resistant Staphylococcus Aureus (MRSA) Treatments Market – Critical Driving Factors

Long-term stays of patients in medical facilities is a key factor boosting MRSA incidences, and the requirement for associated treatments
Innovations in screening technologies and processes for resistant bacterial strains are fuelling the MRSA treatment market
Growth in MRSA infections in hospitals from the high number of COVID-19 patients will contribute to demand.
Tech innovations in terms of machine learning and artificial intelligence in the healthcare sector helps overall market growth

Methicillin-Resistant Staphylococcus Aureus (MRSA) Treatments Market – Major Constraints

Potential for inaccurate results in diagnostics, for MRSA cases is a key obstacle to market growth.
Lack of systematic checkups of MRSA, particularly in developing economies is set to hamper market growth.

Projected Market Impact by COVID-19 Outbreak

The COVID-19 virus is highly contagious, and the outbreak has resulted in an unprecedented number of patients, many of whom require hospitalization. Consequently, the pandemic has substantially increased the risk of secondary, hospital -based infections, including MRSA. Also, COVID-19 patients are more vulnerable to MRSA infections.

Since patients with MRSA are more at risk of fatality, the demand for new antibiotics for MRSA treatment is expected to rise greatly in the short term. Overall demand is likely to decline gradually to pre-pandemic levels once COVID-19 is brought under control.

The methicillin-resistant staphylococcus aureus (MRSA) treatment market report has 96 figures, 63 data tables and a ToC. You can also read about market segmentation on https://www.futuremarketinsights.com/askus/rep-gb-10406

Competition Landscape

Key players in the Methicillin-resistant staphylococcus aureus (MRSA) treatment market include but are not limited to Pfizer Inc., Basilea Pharmaceutica Ltd., Merck & Co. Inc., The Medicines Co., Allergan, and Theravance Biopharma.

Top manufacturers in the market are investing in clinical trials and research & development activities for novel drug molecule formulas and tech, in addition to the introduction of generic medicine for MRSA treatment. For example, researchers have been able to use a novel optical microscopic technique integrating blue laser light on MRSA cell structures. Similarly, researchers have also found promising results from the use of a new drug called Teixobactin.

More about the Report

FMI's market research report gives insights on methicillin-resistant staphylococcus aureus (MRSA) treatment market. The market is analyzed in terms of drug class (glycopeptides, lipopeptides, oxazolidinones, glycylcycline, streptogramins, lincomycin, tetracycline, lipoglycopeptides, antiseptics, naturals, and others), route of administration (intravenous, oral, topical, nasal, cutaneous, and intramuscular) distribution channel (hospital pharmacies, retail pharmacies, drugstores, and online pharmacies), indication (skin and soft tissue infections (SSTIs), pneumonia, bloodstream infections, surgical and medical infections, and others) and types of MRSA (healthcare acquired MRSA, community acquired MRSA, and hospital acquired MRSA) across seven key regions (North America, Latin America, Europe, East Asia, South Asia, Oceania, and Middle East and Africa).

Coverage of FMI's Healthcare, Pharmaceuticals, and Medical Devices Repository

Preterm Birth Diagnostic Test Kits Market: Find insights on the global preterm birth diagnostic test kits market with analysis of major segments, statistics, influencing factors, leading market players, and business strategies used over a 10-year projection period.

Ibuprofen API Market: FMI's report on the global ibuprofen API market gives insights on the market poised for healthy growth during 2019-2029. The study covers restraining factors, revenue streams, market leaders, and market strategies.

Next Generation Optical Biometry Devices Market: Get an analysis on the next generation optical biometry devices market with insights on growth influencers, restraints, opportunities, regional markets, and regulations affecting market players.

About Future Market Insights (FMI)

Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in London, the global financial capital, and has delivery centers in the U.S. and India. FMI's latest market research reports and industry analysis help businesses navigate challenges and take critical decisions with confidence and clarity amidst breakneck competition.

Contact:

Mr. Abhishek Budholiya
Unit No: AU-01-H Gold Tower (AU), Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
MARKET ACCESS DMCC Initiative
For Sales Enquiries: sales@futuremarketinsights.com
For Media Enquiries: press@futuremarketinsights.com
Market Report: https://www.futuremarketinsights.com/reports/methicillin-resistant-staphylococcus-aureus-testing-market
Press Release Source: https://www.futuremarketinsights.com/press-release/methicillin-resistant-staphylococcus-aureus-treatment-market

SOURCE: Future Market Insights

ReleaseID: 594718

FORT LAUDERDALE, FL / ACCESSWIRE / June 22, 2020 / Swisher Hygiene Inc. (the "Company") today announced that it will make a distribution of approximately $10.0 million to its stockholders of record as of June 29, 2020, payable July 15, 2020, at the rate of $0.5657 per share of its outstanding common stock, $.001 par value.

As previously reported in a Current Report on Form 8-K, filed with the Securities and Exchange Commission (the "SEC") on July 1, 2019, the Company, on June 27, 2019, filed a motion with the Court of Chancery of the State of Delaware (the "Delaware Court") seeking the Delaware Court's approval to make an interim distribution to the Company's stockholders of not more than $10.0 million (the "Interim Distribution").

On April 28, 2020, the Delaware Court heard oral arguments from certain purported claimants seeking to substantiate their claims against the Company, and from Honeycrest Holdings, Ltd., opposing the Company's motion for the Interim Distribution, and from the Company in response to the foregoing. On June 12, 2020, in a Letter Opinion, the Delaware Court granted the Company's motion for an Interim Distribution of not more than $10.0 million, set reserves totaling approximately $6.9 million for two claimants while the merits of their claims are being determined, and denied all remaining claims presented to it for consideration.

Pursuant to the Delaware Court's approval of the Company's request for an Interim Distribution of not more than $10.0 million, on June 17, 2020, the Company's Board of Directors considered and approved a distribution to the Company's stockholders of record as of June 29, 2020, of approximately US$10.0 million, calculated at the rate of US$0.5657 per share of the Company's outstanding common stock, $001 par value, payable on July 15, 2020 (the "Payable Date"), and payable in US dollars.

As noted above, the Delaware Court has directed the Company to reserve approximately $6.9 million for the two claims that remain outstanding against the Company. The Company believes that one of those claims, for approximately $4,000, is simply mistaken and appears to be a claim against a company that has never been related to or in any way affiliated with the Company. The other claim relates to the ongoing, 20-plus year litigation between the Company and Honeycrest Holdings, Ltd. Mediation in that matter was held in November 2019, and was unsuccessful. A second New York Court mandated mediation has been scheduled for July 1, 2020. In granting the Company's motion for an Interim Distribution, the Delaware Court found that a reserve for the Honeycrest litigation of $6.9 million, would be "reasonably, in fact amply, likely to satisfy any judgment obtained by Honeycrest." Because of the amount of this reserve, unless it is subsequently reduced by the Delaware Court, the Company does not contemplate making a further distribution to its stockholders until the Honeycrest Holdings, Ltd. claims are dismissed, or otherwise resolved,. The Company cannot reasonably estimate when such dismissal or resolution is likely to happen, or if at such time, the Company will have assets remaining available for distribution to its stockholders.

The Company believes the Interim Distribution announced today will, for U.S. federal income tax purposes, be considered a liquidating distribution and be treated as a return of capital made pursuant to the Company's winding up and liquidation. As such, for U.S. federal income tax purposes, U.S. holders of our common stock generally will recognize a capital gain or loss equal to the difference between the amount of cash distributed to the U.S. holder and its adjusted tax basis in the Company's common stock. A cost recovery approach will generally be applied, and a U.S. holder's full tax basis will generally be recovered before any gain is recognized. Any loss generally will be recognized by a U.S. holder only in the tax year in which the shareholder receives the Company's final liquidating distribution.

Stockholders should consult their own tax advisors for tax advice in connection with the winding up and liquidation. We have not requested a ruling from the U.S. Internal Revenue Service or any other tax authority with respect to the anticipated tax consequences of our winding up and liquidation, and we will not seek an opinion of counsel with respect to the anticipated tax consequences of any liquidating distributions.

In the event any stockholder wishes to update its mailing address or does not receive a distribution as expected and wishes to have a check reissued, it should contact the Company's Transfer Agent, TSX Trust, by email at tmxeinvestorservices@tmx.com, or by telephone 1-866-600-5869 (in North America) or 416-342-1091 (International). Failure by such stockholder to contact the Transfer Agent on or prior to the fifth anniversary of the June 29, 2020 record date for the distribution will result in forfeiture of any entitlement to payment of the distribution that would otherwise be payable to such stockholder.

Cautionary Statement on Forward-Looking Information

All statements other than statements of historical fact contained in this press release constitute "forward-looking information" or "forward-looking statements" within the meaning of the U.S. federal securities laws and the Securities Act (Ontario) and are based on the expectations, estimates and projections of management as of the date of this press release unless otherwise stated. All statements other than historical facts are, or may be, deemed to be forward looking statements. The words "plans," "expects," "is expected," "scheduled," "estimates," or "believes," or similar words or variations of such words and phrases or statements that certain actions, events or results "may," "could," "would," "might," or "will be taken," "occur," and similar expressions identify forward-looking statements.

Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by the Company as of the date of such statements, are inherently subject to significant business, economic and competitive uncertainties and contingencies. All of these assumptions have been derived from information currently available to the Company including information obtained by the Company from third-party sources. These assumptions may prove to be incorrect in whole or in part. All of the forward-looking statements made in this press release are qualified by the above cautionary statements. The forward-looking information set forth in this press release is subject to various assumptions, risks, uncertainties and other factors that are difficult to predict and which could cause actual results to differ materially from those expressed or implied in the forward-looking information. The Company disclaims any intention or obligation to update or revise any forward-looking statements to reflect subsequent events and circumstances, except to the extent required by applicable law.

About Swisher Hygiene Inc.

Swisher Hygiene Inc. closed on the sale of its U.S. operations to Ecolab Inc. on November 2, 2015 and as a result has no remaining operating assets. On Friday, May 27, 2016 (the "Final Record Date"), the Company filed a Certificate of Dissolution. Pursuant to the Plan of Dissolution, and under Delaware law, the dissolution of the Company was effective as of 6:00 p.m. Eastern Time on the Final Record Date. Under Delaware law, the dissolved corporation is continued for three (3) years from the date on which the Certificate of Dissolution was filed, unless extended by direction of the Court of Chancery, to enable the Company's directors to wind up the affairs of the corporation, including the discharge of the Company's liabilities and to distribute to the stockholders any remaining assets. The Court of Chancery has extended the Company's corporate existence on three occasions, most recently through September 30, 2020. Except as discussed in this press release, no assurances can be made as to if or when any shareholder distribution will be made, or the amount of any such distribution, if one is made.

For Further Information, Please Contact:

Swisher Hygiene Inc.
Investor Contact:
Garrett Edson, ICR
Phone: (203) 682-8331

SOURCE: Swisher Hygiene Inc.

ReleaseID: 594728

AI analyzes behavior and performance; real-time Data Axle platform supplies 140+ million prospective B2B and B2C customers

DALLAS, TX / ACCESSWIRE / June 22, 2020 / Marketers can now use AI and real-time, verified third-party data in a single email platform to find new customers more easily thanks to Infogroup's new Acquisition Platform, the company announced today. Infogroup's Artificial Intelligence-driven acquisition platform sifts through more than 140 million emailable prospective B2B and B2C customers, available in its proprietary real-time Data Axle platform, and uses a prospect's known previous behavior to optimize mailings, learning as it goes.

Infogroup, which has supported clients' email campaigns for two decades, built this Acquisition Platform to serve as its new foundational email platform. The platform's decision engine uses event data to give pre- and post-campaign deployment recommendations and optimize targeting and segmentation. Infogroup's acquisition offering includes a full suite of deliverability support services to help clients hit new customer acquisition goals and maximize campaign performance. These services include detailed inbox placement measurement, campaign monitoring, deployment strategies, ISP remediation, and issue resolution if a mailing is blocked or blacklisted.

"Our Acquisition Platform's AI learns from each event and applies that learning across Infogroup's entire database," said Infogroup CEO and Chairman Michael Iaccarino. "Artificial Intelligence is only as good as the data that powers it, and with Infogroup's 140 million emailable, human- and machine-verified business and consumer records, updated in real-time through our Data Axle platform, we're pleased to help our clients find the best prospects."

With data on 74 million consumers and 72 million businesses, Infogroup's Acquisition Platform:

Ensures great cost per acquisition
Improves overall campaign ROI
Generates new leads
Offers creative and campaign management services

Infogroup puts all of its data through regular and rigorous hygiene and validation processes. Its proprietary databases available in the company's flagship platform Data Axle, contain hundreds of demographic and firmographic attributes, enabling Infogroup clients to quickly find the most responsive audiences. Using Infogroup's Acquisition Platform clients can take advantage of a roadmap for multi-touch attribution.

For more information, visit https://www.infogroup.com/acquisition-platform/.

About Infogroup and Data Axle
Infogroup is a leading provider of data and real-time business intelligence solutions for enterprise, small business, nonprofit and political organizations. The company's solutions enable clients to acquire and retain customers, and enhance their user experiences through proprietary business and consumer data, artificial intelligence/machine learning models, innovative software applications and expert professional services. Infogroup's cloud-based Data Axle platform delivers data and data updates in real-time via APIs, CRM integrations, SaaS, and managed services. Infogroup has 45+ years of experience helping organizations exceed their goals. For more information, visit www.infogroup.com.

13155 Noel Rd
Ste 1750
Dallas, TX 75240

PRESS CONTACT

Bill Brazell
bbrazell@witstrategy.com
917-445-7316 cell

SOURCE: Infogroup

ReleaseID: 594673

Casino management systems developers are anticipated to continue investing in tech improvements to bolster the scope of applications in the industry, for a faster recovery after the pandemic ends.

ROCKVILLE, MD / ACCESSWIRE / June 22, 2020 / The gambling business is highly reliant on air-travel and tourism, which in normal conditions requires large numbers of people in close proximity to each other. Consequently, regional and national lockdowns, in addition to social distancing guidelines have hit the industry really hard, substantially impacting the demand for casino management systems.

The global casino management system market has been estimated to rise at an exponential 14.5% CAGR throughout the forecast period between 2019 and 2029. According to Fact.MR, casinos are also largely ineligible for government aid, which hurts market prospects in the near future. However, casino management systems are anticipated to witness a steady resurgence once travel and movement restrictions are eased.

"Casino revenues are dependent on customer retention. Consequently, they focus on boosting service quality and personalization. Gaming clubs incorporate a plethora of systems to collect exhaustive customer and floor operation data. Casino management systems provide these businesses a hub to extract relevant data from varied gambling tools allowing operators to optimize their operations increasing customer loyalty and retention," says the FACT.MR study.

Request report sample of 250+ pages to gain detailed market insights at-

https://www.factmr.com/connectus/sample?flag=S&rep_id=4670

Casino Management System Market- Key Takeaways

Security and surveillance systems account for a major revenue share of casino management systems, driven by need to minimize crimes and cheating on premises.
Analytics tools are gaining substantial traction in casinos to derive insights on game preferences, winning probabilities, spending patterns, and customer behavior.
North America remains the leading consumer of casino management systems owing to high saturation of the gambling industry and faster access to new technology.
Asia Pacific is displaying highly remunerative opportunities owing to rising social acceptance of gambling clubs, relaxation in government regulations, and tax benefits.

Casino Management System Market- Driving Factors

High demand for novel technologies in the gaming industry drives adoption of casino management systems.
Legalization of gambling and the consequent rise in gaming establishments will positively impact the market.
Strong demand by casinos to track player and employee activity is a key contributor to sales.
Government incentives towards the tourism industry and social acceptance of gambling establishments drives growth.

Casino Management System Market- Major Restraints

Rising competition from online gambling practices is a hinderance to the casino management system market.
Strict government regulations associated with gambling will also hold back market developments.

COVID-19 Impact on Casino management system Market

The coronavirus outbreak has had a devastating impact on the gambling market. Gaming operators around the world have been hit. Despite some regions opening to business, spot checking of customers and fears of contagion have kept business sluggish. These trends are anticipated to hinder the casino management system market throughout the duration of the pandemic.

In addition, international travel restrictions and poor transportation make it difficult for customers to visit casinos. Major changes in worker and customer relationships will be essential to sustain and build growth in demand for casino management systems in the months ahead, as the pandemic situation goes back to normal.

The global casino management system market report includes 123 figures, 76 data tables and a table of contents. You can also find a detailed market segmentation on

https://www.factmr.com/report/4670/casino-management-system-market

Competitive Landscape

The casino management systems market is competitive, with a number of small and medium scale businesses in the industry. Major players are investing their resources in researching and developing personalized products, to meet the needs of a wide range of application platforms. For instance, Super Spade Games has partnered with Soft2Bet for supplying casino management systems for live dealer games. Similarly, Vector Solutions has released a system suite of software solutions to help with health checks, exposure tracking, and sanitation tailored for the gambling industry.

Next Level Security Systems Inc., International Game Technology, Aristocrat Leisure Ltd., Konami Corporation, Honeywell International Inc., LGS, and Micros Systems Inc. are some of the leading casino management system developers in the global market.

About the Report

This study offers readers a comprehensive market forecast of the casino management systems market. Global, regional and country-level analysis of the top industry trends impacting the casino management systems market is covered in this FACT.MR study. The report offers insights on the casino management systems market on the basis of application (security & surveillance, analytics, accounting & cash management, player tracking, property management, marketing & promotions, and others) across six regions (North America, Latin America, Europe, East Asia, South Asia & Oceania, and MEA).

Explore FACT.MR's Comprehensive Coverage of ICT Landscape

Car Wash Management System Market– Get the latest insights on the global car wash management system market through FACT.MR's report covering analysis for projection period (2018-2028).

POE Chipsets Market– FACT.MR's study on the global POE chipsets market covers trends, tech advancements, players, and strategies for the course of forecast period (2018-2026).

Quantum Dot Display Market– Obtain comprehensive analysis on the global quantum dot display market through FACT.MR's latest report covering competitive analysis, key regions, along with segmental analysis for 2019-2027.

About Fact.MR

Expert analysis, actionable insights, and strategic recommendations of the veteran research team at FACT.MR helps clients from across the globe with their unique business intelligence requirements. With a repository of over a thousand reports and 1 million+ data points, the team has scrutinized the ICT sector across 50+ countries for over a decade. The team provides unmatched end-to-end research and consulting services. Fact.MR's latest market reports and industry analysis help businesses navigate challenges and take critical decisions with confidence and clarity amidst breakneck competition.

Contact:

Fact.MR
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Email: sales@factmr.com
Web: https://www.factmr.com/
PR- https://www.factmr.com/media-release/1423/global-casino-management-system-market

SOURCE: Fact.MR

ReleaseID: 594720

BEIJING, CHINA / ACCESSWIRE / June 22, 2020 / The research team of Handian Pharmaceutical Medical Center and Handian Traditional Chinese Medicine Hospital has devoted to develop a new formula against COVID-19, which in traditional Chinese medicine theory, is differentiated as cold-dampness viral disease with the symptoms of fever, aversion to cold, cough, fatigue, general aching pain, headache, diarrhea, etc. After several months of hardworking, they initially developed Honee Taishen Granule (also known as Handian HD1). Cooperating with Chinese Academy of Medical Sciences and Good Laboratory Practice (GLP) certification agencies, Handian Pharmaceutical Medical Center has completed pharmacy studies. Pharmacology and toxicology tests are still in progress to further evaluate its safety and efficacy.

This formula is derived from a famous traditional Chinese medicine prescription. Its components can eliminate dampness and turbidity, repel foulness and remove toxin, which give it cold-dampness eliminating and antiviral effects. According to traditional Chinese medicine theory, it rectifies taiyin cold damp constitution and restores yin-yang balance of the body, which can help patients regain immunity and prevents the virus from affecting the spleen (pancreas) to damage the body.

Contact:

Xiaoteng Bai
Beijing Handian Science & Technology (Group) Co., Ltd.
Phone: +86 010 5690 3502
Website: http://www.handian.com

SOURCE: :Beijing Handian Science & Technology (Group) Co., Ltd.

ReleaseID: 594856